- 1 Prevalence, treatment, and factors associated with cryptococcal meningitis post introduction
- 2 of integrase inhibitors antiretroviral based regimens among people living with HIV in
- 3 Tanzania
- 4 Makyao Minja<sup>1</sup>, Tusaligwe Mbilinyi<sup>2</sup>, Bryceson Mkinga<sup>3</sup>, Erick G. Philipo<sup>4</sup>, Joyce Owenya<sup>5</sup>, and
- 5 Manase Kilonzi<sup>1\*</sup>
- 6 Affiliations

17

18

19

20

- 7 Department of Clinical Pharmacy and Pharmacology, School of Pharmacy, the Muhimbili
- 8 University of Health and Allied Sciences, Dar es Salaam, Tanzania.
- <sup>2</sup>Department of Pharmaceutical Microbiology, School of Pharmacy, the Muhimbili University of
- Health and Allied Sciences, Dar es Salaam, Tanzania.
- <sup>3</sup>Department of Pharmacognosy, School of Pharmacy, the Muhimbili University of Health and
- 12 Allied Sciences, Dar es Salaam, Tanzania.
- <sup>4</sup>Department of Pharmaceutics and Pharmacy Practice, School of Pharmacy, the Muhimbili
- 14 University of Health and Allied Sciences, Dar es Salaam, Tanzania.
- <sup>5</sup>Department of Pharmacy, Temeke Regional Referral Hospital, Dar es Salaam, Tanzania.
- 16 Corresponding author: manasekilonzi@gmail.com, +255 688 045752

21

22

23

24

25

26

27

28

29

30

31

32

33

34

35

36

37

38

39

40

41

42

Tanzania

**Abstract Objective:** This study aimed to assess the prevalence of CM, treatment practice, and the associated factor's post-introduction of Tenofovir Lamivudine and Dolutegravir (TLD) regimen among PLHIV in Tanzania. **Methods:** This was an analytical cross-sectional study, and the data was collected retrospectively in three public regional referral hospitals (RRHs) in Dar es Salaam, Tanzania. A total of 405 files of the PLHIV admitted in the medical wards on the TLD regimen from January 2019 to December 2022 were reviewed. The collected information includes patient demographic characteristics, Cryptococcal status, CD4 level at the time of CM diagnosis, status of using ART, CM treatment approach, and outcome. Data was analyzed using SPSS software version 23. Results: Out of 405, the majority 267(65.9%) were female, 224(55.3%) were aged between 36 -55 years, and 293(72.3%) married. ART defaulters were found to be 37(9.1%). The prevalence of CM was found to be 48(11.9%), out of which 42(87.5%) received fluconazole alone. ART defaulter and marital status significantly (p-value < 0.05) were associated with those who tested CM positive. Conclusion: The study found the prevalence of CM among PLHIV to be significantly high and the majority were treated with fluconazole alone. ART defaulters and marital status were significantly associated with one being CM positive. Responsible authorities and stakeholders should enforce guideline adherence and PLHIV should be encouraged on medication adherence. Keywords: Cryptococcal meningitis, Fluconazole, Triple therapy, Prevalence, Treatment,

#### I. Introduction

43

44

45

46

47

48

49

50

51

52

53

54

55

56

57

58

59

60

61

62

63

64

65

Cryptococcal Meningitis (CM) is one of the leading causes of laboratory-confirmed meningitis in adults living in countries with a high burden of HIV especially in Sub-Saharan Africa (SSA) [1,2]. CM accounts for over 100,000 incident cases of meningitis per year in the SSA [3]. The burden of CM in PLHIV is high and globally is estimated to cause 15%-20% of HIV-related deaths. In lowincome countries (LICs) 220,000 cases of CM are estimated per year resulting in 181,000 deaths [4]. In Tanzania, reports have shown that cryptococcosis has 50% fatality at any dose of antifungal given [5]. CM is an opportunistic fungal infection usually affecting immune-compromised hosts like People Living with Human Immune-deficiency Virus (PLHIV), diabetic patients, solid organ transplant recipients, and patients receiving immunosuppressant [6]. The infection is not transferred from person to person, but results from the inhalation of infectious spores mainly found in bird droppings, that multiply in the lungs and can spread to the membranes covering the brain and spinal cord causing meningitis [7]. In HIV-infected patients, the disease is considered as a result of recurrence of latent infection which occurs months to years after the initial exposure event [8,9]. In 2019, Tanzania introduced a Dolutegravir (DTG) based regimen of TLD as the preferred firstline antiretroviral therapy (ART) for most adults and adolescents for HIV-1 infections [10]. From the two landmark clinical trials named ADVANCE and NAMSAL performed in SSA, the efficacy of DTG, and non-emergence of resistance support its use as a first-line regimen for ART-naïve adults with HIV-1 [11]. Patients on the DTG-based regimen had high weight and the viral load was suppressed more quickly compared to the Efavirenz-based regimen [12]. TLD is affordable and well tolerated and improves the clinical outcomes of patients) [13,14]. On the other hand, triple therapy of Amphotericin B, flucytosine (5-FC), and fluconazole is recommended for the treatment

of CM. The guidelines recommend two weeks of amphotericin B and 5-FC for the induction phase, followed by fluconazole for the merging and maintenance phases of treatment [15]. Studies report that the use of fluconazole alone is inferior and is associated with high morbidity and mortality compared to triple therapy [16]. However, despite advances in HIV, and CM management, the majority of PLHIV-living LICs face hospital acute mortality in the range between 30-50% [17]. Other factors associated with the burden of CM among PLHIV are reported to be; Being ART naïve and ART defaulter, being male, living in rural areas, being hospitalized, having low CD4 count, and having increasing age with CD4<100 cells, and having body mass index of <18.5kg/m<sup>2</sup>[18]. Making age, gender, body mass index, and ART adherence major determining factors for cryptococcal infection among PLHIV [19]. Similar to other World Health Organization (WHO) member states, Tanzania adopted the use of a integrase inhibitors-based ART regimen as first-line therapy for adults with PLHIV, and through its guidelines, triple therapy was introduced for the management of CM. Despite the efforts made by the WHO and its member states, the majority of deaths among PLHIV are associated with CM [20]. However, there is a scarcity of information with regard to the prevalence of CM and treatment practice's post-introduction of integrase inhibitors-based regimens as first-line therapy for PLHIV in LICs. Therefore, this study aims to determine the prevalence, treatment practice, and associated factors of CM among PLHIV post-introduction of TLD in Dar es Salaam, Tanzania.

## II. Materials and Methods

66

67

68

69

70

71

72

73

74

75

76

77

78

79

80

81

82

83

84

85

86

#### A. Study design and area

- This was a hospital-based cross-sectional study using a retrospective data collection approach.
- Data were collected from March to June 2023 in public regional referral hospitals (RRHs) in Dar

es Salaam, Tanzania i.e., Temeke, Amana, and Mwananyamala referral hospitals. The chosen hospitals have Care and Treatment Centers (CTC) that serve the majority of PLHIV residing in Dar es Salaam city and surrounding areas.

## B. Study population

People Living with HIV (PLHIV) admitted to the medical wards on TLD from 2019 to 2022 in the three RRHs (Temeke, Amana, and Mwananyamala).

## C. Sample size and sampling technique

A minimum sample size of 153 PLHIV was estimated using the formula for cross-sectional study  $(n = p(1-p) z^2/d^2)$ . Assuming a population of 7.1% from a previous study on the "burden of serious fungal infection" conducted in Tanzania[6], the confidence level of 95% (z = 1.96) and precision (d) of 5%,. On data collection, a total of 405 PLHIV on TLD admitted to the medical wards from 2019 to 2022 files were retrieved in the three visited RRHs.

## D. Data collection

An Excel spreadsheet was used to collect data from patients' files, laboratory test results, and Care and Treatment Clinic (CTC) cards where sections involving treatment practice and associated factors were included, as information about associated risk factors, treatment practice, and prevalence was obtained. The information was collected with the assistance of the respected facility's responsible healthcare worker. On days of data collection data collectors were given files of the HIV patients admitted in medical wards from 2019 to 2022 from the archives. To observe confidentiality names and other information which could identify the participant were not documented.

E. Data analysis

Data obtained was analyzed by using Statistical Package for Social Science (SPSS) software, version 23. Descriptive statistics was used to summarize socio-demographic and clinical characteristics; the Chi-square test was used to analyze variables associated with the prevalence of CM and treatment outcomes among those who tested CM positive. A p-value below 0.05 was considered statistically significant.

### F. Ethical issues

Ethical clearance was obtained from the Muhimbili University of Health and Allied Sciences (MUHAS)- Research Ethics Committee (REC). The protocol stated clear that the study will retrieve information from patients medical records and the clearance was issued MUHAS-REC: Ref. No. DA. 283/298/01L/602). Permission from the three RRHs administrations (Temeke, Amana, and Mwananyamala) was sought before data collection. Patients' files were obtained from medical file archives and special identification number was assigned for each file to protect confidentiality of the participants information. Participants name and another information that could identify the participants were not abducted from the files.

#### III. Results

## A. Demographic characteristics of study participants

Out of 405 participants, the majority 224 (55.3%) were between 36-55 years followed by 98(24.2%), 18-35 years of age. Regarding employment status, the majority 167(41.2%) were self-employed and 293(72.3%) were married. Besides, most 267(65.9%) of the participants were female and 37(9.1%) were ART defaulter(**table1**).

Table 1: Demographic characteristics of study participants (n=405)

Variables	Median (Range)	n(%)	
Age (years)	43 (2-78) years		
Age category (years)			
<18		28(6.9)	
18-35		98(24.2)	
36-55		224(55.3)	
>55		55(13.6)	
Sex			
Female		267 (65.9)	
Male		138 (34.1)	
Occupation			
Employed		150(37.0)	
Self-employed		167(41.2)	
Unemployed		88(21.7)	
Marital status			
Married		293(72.3)	
Unmarried		112(27.7)	
ART Defaulter			
Yes		37(9.1)	
No		368(90.9)	

131

# B. Prevalence of CM, CD4 count at diagnosis, treatment approach and Outcome of treatment among participants

Out of 405 participants, 48 (11.9%) tested CM positive. Of those who tested positive, 6(12.5%) received triple therapy (fluconazole, 5FC, and amphotericin) while 42(87.5%) received fluconazole alone. Following treatment, 4(8.9%) died, 18(40%) recovered, 17(37.8%) were lost to follow-up, 2(4.4%) were given referral, and 4(8.9%) were on going with treatment (**table 2**).

Table 2: Prevalence of cryptococcal meningitis, CD4 count at diagnosis, treatment approach, and Outcome of treatment among participants (n=405)

Variable	n(%)
Cryptococcal meningitis status (n =405)	
Positive	48(11.9)
Negative	357(88.1)
CD4 count (cells/μL) at diagnosis Cryptococcal meningitis (n =48)	
<200	39(81.3)
≥200	9(18.8)
Treatment regimen used (n=48)	
flu, 5FC, and amphotericin B	6(12.5)
fluconazole	42(87.5)
Treatment Outcomes (n=45)	
Died	4(8.9)
Recovered	18(40)
Loss To Follow up	17(37.8)

Referred	2(4.4)
On treatment	4(8.9)

# C. Factors associated with CM status among study participants

Following Pearson chi-square test, all 37 (100%) ART defaulters tested CM positive compared to non-defaulters; the difference was statistically significant (p-value < 0.01). While those unmarried 24(21.4%) significantly (p-value < 0.01) tested CM positive compared to those who are in marriage 24(8.1%). Other factors including age, sex, and occupation were not associated with being CM-positive among the participants (**table 3**).

Table 3: Showing Pearson chi-square test of the demographic characteristics and Cryptococcal meningitis status among participants (n = 405)

Variables	Cryptococcal m	Cryptococcal meningitis status		
Age (years)	Positive	Negative		
Age category (years)	I	I		
<18	0(0.0)	28(100)		
18-35	17(17.3)	81(82.7)		
36-55	25(11.2)	199(88.8)	0.80	
>55	6(10.9)	49(89.1)		
Sex				
Female	23(16.7)	115(83.3)		
Male	25(9.4)	242(90.6)	0.31	

Employed	8(9.1)	80(90.9)	
Self-employed	20(13.2)	132(86.8)	0.64
Unemployed	20(12.1)	145(87.9)	
Marital status			
Married	24(8.2)	269(91.8)	
Unmarried	24(21.4)	88(78.6)	< 0.01
ART defaulter	I	I	
Yes	37(100)	0(0.0)	
No	11(3.0)	357(97.0)	< 0.01

# D. Factors associated with Cryptococcal meningitis treatment outcomes among study participants

Among those who were given a recommended regimen none died, none neither had loss to follow up nor referral, 3(60.0%) recovered and 2(40%) were on going with treatments while among those given fluconazole alone; 4(10%) died, 15(37.5%) recovered, 17(42.5%) were loss to follow up, 2(5%) were referred and 2(5%) are ongoing with treatment and the difference were slightly significant (p-value = 0.048). Other factors like age, sex, occupation, marital status, ART defaulter status, and CD4 count at the time of diagnosis were not statistically related to CM treatment outcome. However, for those who had a CD4 count < 200 cells/ $\mu$ L at the time of diagnosis, 4 (11.1%) died, and 12(33.3%) recovered while those who had a CD4 count of  $\geq 200$  cells/ $\mu$ L none died, 6(66.7%) recovered (table 4)

**Table 4:** Showing Pearson chi-square test of the demographic characteristics and Cryptococcal meningitis status among participants (n=45)

Variable	Treatme	Treatment Outcomes n (%)				
	Died	Recovere	Loss To Follow	Referred	On	
		d	up		treatment	
Age category						
<18	0(0.0)	0(0.0)	0(0.0)	0(0.0)	0(0.0)	
18-35	0(0.0)	7(46.7)	7(46.7)	1(6.7)	0(0.0)	0.31
36-55	2(8.3)	10(41.7)	8(33.3)	1(4.2)	3(12.5)	
>55	2(33.3)	1(16.7)	2(33.3)	0(0.0)	1(16.7)	
Sex						
Male	3(14.3)	9(42.9)	7(33.3)	1(4.8)	1(4.8)	
Female	1(4.2)	9(37.5)	10(41.7)	1(4.2)	3(12.5)	0.68
Occupation						
Unemployed	0(0.0)	2(28.6)	4(57.1)	1(14.3)	0(0.0)	
Employed	1(5.0)	7(35.0)	10(50.0)	0(0.0)	2(10.0)	0.28
Self employed	3(16.7)	9(50.0)	3(16.7)	1(5.6)	2(11.1)	
Marital status						
Married	3(13.6)	11(50.0)	7(31.8)	0(0.0)	1(4.5)	
Unmarried	1(4.3)	7(30.4)	10(43.5)	2(8.7)	3(13.0)	0.25
ART defaulter						
Yes	3(8.8)	14(41.2)	12(35.3)	1(2.9)	4(11.8)	
No	1(9.1)	4(36.4)	5(45.5)	1(9.1)	0(0.0)	0.69
CD4 count at diag	 gnosis (cells	s/μL)				
<200	4(11.1)	12(33.3)	15(41.7)	2(5.6)	3(8.3)	

≥200	0(0.0)	6(66.7)	2(22.2)	0(0.00)	1(11.1)	0.37
Treatment regimen						
Flu,5FC,	0(0.0)	3(60.0)	0(0.0)	0(0.0)	2(40.0)	
amphotericin						0.048
Fluconazole	4(10.0)	15(37.5)	17(42.5)	2(5.0)	2(5.0)	

#### IV. Discussion

The objective of this study was to determine the prevalence, treatment, and factors associated with CM post-introduction of TLD regimen among PLHIV in Tanzania. Out of 405 reviewed patient files, the study found that 11.9% had CM, out of which 12.5% received the recommended regimen (triple therapy = Fluconazole, 5-FC, and amphotericin B) and 87.5% received fluconazole alone. Following treatment, 40% recovered while 37.8% were lost to follow-up. ART defaulter and marital status were significantly associated with those who tested CM positive; neither of those treated with triple therapy died, referred, or lost to follow-up compared to those on fluconazole alone.

The prevalence observed in our study is comparable to what was observed in developing countries like Cameroon (11.2%), and Ethiopia (11.4%) [21,22]. The reported prevalence is slightly higher than what was observed in Sierra Leone (7.7%) and Indonesia (7.1%) and higher than what was reported in London (5%), Nigeria (5.1%) and Haiti (1.1%) [23,24]. Varying prevalence's of CM were observed in different studies could be due to the type of the study design and data collection approaches. Also, some studies included all naive and experienced PLHIV patients while others recruited only those on ART for some time. Our studies assess the CM status of the PLHIV

180

181

182

183

184

185

186

187

188

189

190

191

192

193

194

195

196

197

198

199

200

201

202

admitted in the hospital for medical reasons which could explain the observed high prevalence. Nevertheless, differences in laboratory protocol, healthcare system, and geographical location of the study settings have been associated with the inconsistency of the reported CM prevalence among PLHIV [25,26]. Since CM is acquired through inhalation of the yeast droplet from the air, weather condition differences may also influence the reported prevalence. The study demonstrated that only 12.5% of those with CM were treated with the recommended regimen which is a combination of Amphotericin B and 5-FC during the induction course and Fluconazole during the completion phase. The uses of Amphotericin B and flucytosine are reported to reduce CM-related mortality by 40% and clinical trials report that the use of fluconazole alone in the management of CM is inferior [16]. Similar to findings from this study PLHIV with CM treated with fluconazole alone, the majority died or were lost to follow-up compared to those given triple therapy. Despite being recommended by WHO and adopted by member countries like Tanzania, the use of triple therapy in the management of CM in most of the developing countries is low [27]. The poor availability of 5-FC and amphotericin B and the associated cost of purchasing the two medications could be a reason for their poor use in developing countries [28]. The use of a drug like amphotericin B requires laboratory tests prior to and during the time of using the drug in order to prevent patients from toxicity [29]. The latter increases the cost of treatment, taking into consideration that the majority of people in developing countries rely on out-of-pocket mode of payment and the level of poverty could be a reason why healthcare providers (HCPs) opt to use fluconazole alone [30]. In addition, triple therapy involves a different route of drug administration, as fluconazole and 5-FC are given by infusion, and amphotericin B is given intrathecally. The competency of administering amphotericin B among HCPs and the complexity of monitoring for toxicity could

203

204

205

206

207

208

209

210

211

212

213

214

215

216

217

218

219

220

221

222

223

224

be another reason why most HCPs opt for the use of fluconazole alone [31] Training of the HCPs and people involved in the care of PLHIV on how to use triple therapy should be in place to equip HCPs with knowledge and skills on how to dose and administer the medications [28]. Nevertheless, in Tanzania, as in other developing countries patients appear late in the hospital and PLHIV with CM end up admitted and treated as an inpatient through a medical ward. However, medicines and consumables for PLHIV which are purchased and sent to the facilities through a vertical program are available in the CTC. Therefore, proper communication should be initiated to ensure PLHIV admitted in the wards receive medications from CTC. The latter will foster the use of triple therapy as fluconazole, 5-FC, and amphotericin B are grouped as drugs for opportunistic infections (OIs) and are procured through vertical programs [29,32]. The study also observed that ART defaulters were significantly associated with those who tested CM positive. The findings are consistent with what has been reported repeatedly that stopping the use of ART leads to increased viral load, suppressing CD4 cells, and exposing patients to OIs like CM. HIV infection is the common risk of CM, as the risk is estimated to be 95% in PLHIV living in middle-low-income countries and 80% in high-income countries. Despite TLD being effective and user-friendly, current studies still report inadequate adherence to ART among PLHIV [33,34]. Although WHO recommends screening for CM to PLHIV with CD4 levels < 100/ul and naive, studies report the significant prevalence of CM among ART-experienced patients. To fight against the deadly disease, screening for CM among PLHIV should be done regularly despite the CD4 level and years of being on ART [18]. Furthermore, the use of fluconazole as prophylaxis should be scaled up to all PLHIV, particularly in developing countries where the majority have immune problems and access to medical care is a challenge [35]. The latter is possible by taking the

example of Isoniazid prophylaxis therapy (IPT) for the prevention of tuberculosis among PLHIV [19].

The study found that the prevalence of CM was higher among unmarried people compared to

married people. Several studies report the importance of PLHIV having a close relative/friend or spouse be aware of his/her status [36,37]). Advantages of disclosing HIV status include reducing the level of stigma, having someone to remind a patient to take medication, and clinic schedules and it improves the quality of living [38]. Therefore, more efforts should be implemented to ensure that the majority of PLHIVs disclose the status at least to one of the close spouses/relative or friend. Moreover, our study found no significant difference in CM prevalence between males and females. The findings are not similar to what was reported in other studies in which the prevalence of CM was high in males compared to females [20]. The difference observed could be due to the study setting; our study was conducted in the city of Dar es Salaam, in which both men and women are considered breadwinners of the family [39]. Therefore, being outdoors both men and women are equally exposed to contaminated environments.

#### V. Conclusion

The study found the prevalence of CM among PLHIV to be significantly high. Unlike the guideline recommendation, the majority of PLHIV with CM were treated with fluconazole alone instead of triple therapy. ART defaulters and marital status were significantly associated with one being CM positive. Responsible authorities and stakeholders should enforce guideline adherence and a mechanism should be instituted to ensure PLHIV adheres to medication. Taking an example of tuberculosis treatment, in which a victim must visit the clinic with a relative, strategies should be proposed to ensure PLHIV discloses their status to at least a spouse/relative or a close friend.

VI. List of abbreviation

247

254

- 5-FC: 5-fluorocytosine(Flucytosine), ART: Antiretroviral Therapy, CTC: Care and Treatment
- 249 Centre, CD4: Clusters of Differentiation 4, CM: Cryptococcal meningitis, PLHIV: People Living
- 250 With Human Immunodeficiency Virus, HIV: Human Immunodeficiency Virus, HCPs: Health
- 251 Care Providers, **IPT**: Isoniazid Prophylaxis Therapy, **LIC**: Lower Income Countries, **MUHAS**:
- Muhimbili University of Health and Allied Sciences, **RRH**: Regional Referral Hospitals, **SPSS**:
- 253 Statistical Package for Social Science, TLD: Tenofovir Lamivudine Dolutegravir

### VII. Acknowledgements

- 255 The authors sincerely thank the Muhimbili University of Health and Allied Sciences Research
- and Ethics Committee (MUHAS-REC) for providing ethical clearance and administration of the
- visited hospitals for providing permission to conduct data collection. We also thank each appointed
- 258 hospital HCP who helped data collectors to retrieve files and clarified some of the unexplained
- 259 information.

#### 260 VIII. References

- 1. Kisenge PR, Hawkins AT, Maro VP, Mchele JPD, Swai NS, Mueller A, et al. Low CD4
- 262 count plus coma predicts cryptococcal meningitis in Tanzania. BMC Infect Dis. 2007;7: 1–
- 263 5. doi:10.1186/1471-2334-7-39.
- 264 2. Britz E, Perovic O, Von Mollendorf C, Von Gottberg A, Iyaloo S, Quan V, et al. The
- epidemiology of meningitis among adults in a south African province with a high HIV
- prevalence. 2009-2012. PLoS One. 2016;11: doi:10.1371/journal.pone.0163036.
- 3. Muzazu SGY, Assefa DG, Phiri C, Getinet T, Solomon S, Yismaw G, et al. Prevalence of

- cryptococcal meningitis among people living with human immuno-deficiency virus and predictors of mortality in adults on induction therapy in Africa: A systematic review and meta-analysis. Front Med. 2022;9: 1–13. doi:10.3389/fmed.2022.989265
- 4. Radha Rajasingham, Rachel M Smith, Benjamin J Park, Joseph N Jarvis, Nelesh P
  Govender, Tom M Chiller et al. Global burden of disease of HIV-associated cryptococcal
  meningitis: an updated analysis. Lancet Infect Dis. 2017;17(8):873-881. doi:
  10.1016/S1473-3099(17)30243-8.
- 5. Faini D, Maokola W, Furrer H, Hatz C, Battegay M, Tanner M, et al. Burden of serious fungal infections in Tanzania. Mycoses. 2015;58: 70–79. doi:10.1111/myc.12390.
- Teekaput C, Yasri S, Chaiwarith R. Cryptococcal Meningitis: Differences between Patients
   with and without HIV-Infection. Pathogens. 2023;12. doi:10.3390/pathogens12030427.
- Baddley JW, Schain DC, Gupte AA, Lodhi SA, Kayler LK, Frade JP, et al. Transmission
   of Cryptococcus neoformans by organ transplantation. Clin Infect Dis. 2011;52: 94–98.
   doi:10.1093/cid/ciq216.
- Joel Schop. Protective immunity against cryptococcus neoformans infection. McGill J Med.
   2007;10: 35–43. doi:10.26443/mjm.v10i1.467.
- 9. Ngan NTT, Flower B, Day JN. Treatment of Cryptococcal Meningitis: How Have We Got
  Here and Where are We Going? Drugs. 2022;82: 1237–1249. doi:10.1007/s40265-02201757-5
- NASP. National Guidelines for the Management of HIV and AIDS. Development. 2019;7:
   2,274,923,575.

- 289 11. Calmy A, Tovar Sanchez T, Kouanfack C, Mpoudi-Etame M, Leroy S, Perrineau S, et al.
- Dolutegravir-based and low-dose efavirenz-based regimen for the initial treatment of HIV-1
- infection (NAMSAL): week 96 results from a two-group, multicentre, randomised, open
- label, phase 3 non-inferiority trial in Cameroon. Lancet HIV. 2020;7: e677–e687.
- 293 doi:10.1016/S2352-3018(20)30238-1
- 294 12. de Faria Ferreira M, Brito-Santos F, Henrique Nascimento Theodoro P, de Abreu Almeida
- 295 M, Lazera M dos S, Trilles L. Mixed infection by Cryptococcus neoformans and
- 296 Cryptococcus gattii and coinfection with paracoccidioidomycosis in PLHIV. Med Mycol
- 297 Case Rep. 2022;35: 48–50. doi:10.1016/j.mmcr.2022.01.006
- 298 13. Ouedraogo D, Cissoko Y, Soumare M, Alle Akakpo AE, Loua O-O, Konate I, et al.
- Neuromeningeal Cryptococcosis and Tuberculosis Coinfection in Bamako: A One-Year
- 300 Case Series. Open Forum Infect Dis. 2023;10: 1–4. doi:10.1093/ofid/ofad438
- 301 14. Perfect JR, Dismukes WE, Dromer F, Goldman DL, John R, Hamill RJ, et al. Guideline for
- 302 cryptococcus. Clin Infect Dis. 2018;50: 291–322. doi:10.1086/649858.Clinical
- 303 15. Miot J, Leong T, Takuva S, Parrish A, Dawood H. Cost-effectiveness analysis of flucytosine
- as induction therapy in the treatment of cryptococcal meningitis in HIV-infected adults in
- 305 South Africa. BMC Health Serv Res. 2021;21: 1–11. doi:10.1186/s12913-021-06268-9
- 306 16. Loyse A, Dromer F, Day J, Lortholary O, Harrison TS. Flucytosine and cryptococcosis:
- Time to urgently address the worldwide accessibility of a 50-year-old antifungal. J
- 308 Antimicrob Chemother. 2013;68: 2435–2444. doi:10.1093/jac/dkt221
- 309 17. Longley N, Muzoora C, Taseera K, Mwesigye J, Rwebembera J, Chakera A, et al. Dose

response effect of high-dose fluconazole for HIV-associated cryptococcal meningitis in 310 southwestern Uganda. Clin Infect Dis. 2008;47: 1556–1561. doi:10.1086/593194 311 Abassi M, Boulware DR, Rhein J. Cryptococcal Meningitis: Diagnosis and Management 312 18. Update. Curr Trop Med Reports. 2015;2: 90–99. doi:10.1007/s40475-015-0046-y 313 19. Hailu K, Niguse S, Hagos K, Abdulkader M. Cryptococcal antigenemia and associated risk 314 factors among ART-naïve and ART-experienced HIV-infected peoples at selected health 315 institutions of Mekelle, Northern Ethiopia. Microbiologyopen. 316 2019;8: 1–8. 317 doi:10.1002/mbo3.746 318 20. Negash M, Wondmagegn T, Tajebe F. Opportunistic Cryptococcal Antigenemia in the HAART Era at HIV Epidemic Settings of Northwest Ethiopia. Can J Infect Dis Med 319 Microbiol. 2020;2020. doi:10.1155/2020/5017120 320 321 21. Jemal M, Deress T, Belachew T, Adem Y. Prevalence of Cryptococcal Antigenemia and 322 Associated Factors among HIV / AIDS Patients at Felege-Hiwot Referral Hospital, Bahir Dar, Northwest Ethiopia. 2021;2021. 323 22. Luma HN, Temfack E, Halle MP, Nguenkam Tchaleu BC, Mapoure YN, Koulla-Shiro S. 324 325 Cryptococcal meningoencephalitis in human immunodeficiency virus/acquired 326 immunodeficiency syndrome in Douala, Cameroon: A cross sectional study. N Am J Med Sci. 2013;5: 486–491. doi:10.4103/1947-2714.117318 327 Lakoh S, Rickman H, Sesay M, Kenneh S, Burke R, Baldeh M, et al. Prevalence and 23. 328 329 mortality of cryptococcal disease in adults with advanced HIV in an urban tertiary hospital in Sierra Leone: A prospective study. BMC Infect Dis. 2020;20: 1–7. doi:10.1186/s12879-330

- 331 020-4862-x
- 332 24. Geda N, Beyene T, Dabsu R, Mengist HM. Prevalence of Cryptococcal Antigenemia and
- associated factors among HIV/AIDS patients on second-line antiretroviral therapy at two
- hospitals in Western Oromia, Ethiopia. PLoS One. 2019;14: 1–13.
- doi:10.1371/journal.pone.0225691
- 336 25. Molloy SF, Chiller T, Greene GS, Burry J, Govender NP, Kanyama C, et al. Cryptococcal
- meningitis: A neglected NTD? PLoS Negl Trop Dis. 2017;11: 1–7.
- 338 doi:10.1371/journal.pntd.0005575
- 339 26. Kaplan JE, Vallabhaneni S, Smith RM, Chideya-Chihota S, Chehab J, Park B. Cryptococcal
- antigen screening and early antifungal treatment to prevent cryptococcal meningitis: A
- review of the literature. J Acquir Immune Defic Syndr. 2015;68: S331–S339.
- doi:10.1097/QAI.0000000000000484
- 343 27. WHO. Guidelines for the diagnosis, prevention and management of cryptococcal disease.
- 344 2018.
- Loyse A, Burry J, Cohn J, Ford N, Chiller T, Ribeiro I, et al. Leave no one behind: response
- to new evidence and guidelines for the management of cryptococcal meningitis in low-
- income and middle-income countries. Lancet Infect Dis. 2019;19: e143–e147.
- doi:10.1016/S1473-3099(18)30493-6
- 349 29. Molloy SF, Kanyama C, Heyderman RS, Loyse A, Kouanfack C, Chanda D, et al.
- Antifungal Combinations for Treatment of Cryptococcal Meningitis in Africa. N Engl J
- 351 Med. 2018;378: 1004–1017. doi:10.1056/nejmoa1710922

30. Kitole FA, Lihawa RM, Mkuna E. Equity in the public social healthcare protection in 352 Tanzania: does it matter on household healthcare financing? Int J Equity Health. 2023;22: 353 1–14. doi:10.1186/s12939-023-01855-0 354 Cavassin FB, Baú-Carneiro JL, Vilas-Boas RR, Queiroz-Telles F. Sixty years of 355 31. Amphotericin B: An Overview of the Main Antifungal Agent Used to Treat Invasive Fungal 356 Infections. Infect Dis Ther. 2021;10: 115–147. doi:10.1007/s40121-020-00382-7 357 isangula KG. Prevention of Mother to Child Transmission of HIV Program in Tanzania: 32. 358 **SSRN** 359 Service Delivery and Uptake Constraints. Electron J. 2012. doi:10.2139/ssrn.1976890 360 Kilapilo MS, Sangeda RZ, Bwire GM, Sambayi GL, Mosha IH, Killewo J. Adherence to 361 33. Antiretroviral Therapy and Associated Factors Among People Living With HIV Following 362 363 the Introduction of Dolutegravir Based Regimens in Dar es Salaam, Tanzania. J Int Assoc Provid AIDS Care. 2022;21: 1–8. doi:10.1177/23259582221084543 364 34. Alufandika M, Lawrence DS, Boyer-Chammard T, Kanyama C, Ndhlovu CE, Mosepele M, 365 et al. A pragmatic approach to managing antiretroviral therapy-experienced patients 366 diagnosed with HIV-associated cryptococcal meningitis: Impact of antiretroviral therapy 367 adherence and duration. Aids. 2020;34: 1425–1428. doi:10.1097/QAD.000000000002556 368 35. Katende A, Mbwanji G, Faini D, Nyuri A, Kalinjuma AV, Mnzava D, et al. Short-course 369 370 amphotericin B in addition to sertraline and fluconazole for treatment of HIV-associated cryptococcal meningitis in rural Tanzania. Mycoses. 2019;62: 1127–1132. 371

372

doi:10.1111/myc.12995

373 36. Xu JF, Ming ZQ, Zhang YQ, Wang PC, Jing J, Cheng F. Family support, discrimination, and quality of life among ART-treated HIV-infected patients: A two-year study in China. 374 Infect Dis Poverty. 2017;6: 1–10. doi:10.1186/s40249-017-0364-5 375 37. Banagi Yathiraj A, Unnikrishnan B, Ramapuram JT, Kumar N, Mithra P, Kulkarni V, et al. 376 Factors Influencing Adherence to Antiretroviral Therapy among People Living with HIV in 377 South India. J Int Assoc Provid AIDS Care. 378 2016;15: 529–533. 379 doi:10.1177/2325957416661424 38. Hallberg D, Kimario TD, Mtuya C, Msuya M, Björling G. Factors affecting HIV disclosure 380 among partners in Morongo, Tanzania. Int J Africa Nurs Sci. 2019;10: 49–54. 381 doi:10.1016/j.ijans.2019.01.006 382 39. Ezeanolue EE, Nwizu C, Greene GS, Amusu O, Chukwuka C, Ndembi N, et al. Brief 383 384 Report: Geographical Variation in Prevalence of Cryptococcal Antigenemia among HIV-Infected, Treatment-Naive Patients in Nigeria: A Multicenter Cross-Sectional Study, J 385 Acquir Immune Defic Syndr. 2016;73: 117–121. doi:10.1097/QAI.000000000001048 386

387